Frontline plc
FROFrontline plc's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: the price moved +107.3% in a year while annual EPS moved −23.8% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (37 weeks in) while the P/E sits at the 60th percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +1,766.7% year on year, and 148% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Frontline plc trades at $39.0, in a confirmed uptrend and 37 weeks into that stage. That is +23.7% against its own 200-day average. It sits at 91% of a 52-week range of $19 to $41. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 37 of stage 2. At $39.0 it trades +23.7% versus its 200-day average and sits at 91% of its 52-week range ($19–$41).
Against the market, two honest reads. Cumulative: over the last 10.1 years the stock moved +418% while the S&P 500 moved +263% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Frontline plc trades at 9.6× P/E, mid-range by its own standards (60th percentile). Its long-run median P/E is 8.9×, measured across 4.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 9.6× is mid-range by its own standards (60th percentile), against a long-run median of 8.9× measured over 4.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −23.8% against a +107.3% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the +31.2%/yr price move, ~+3.1%/yr came from earnings growth and ~+28.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Frontline plc reads as turning around on its fundamental arc. Turning around — EPS growth swung from −59.8% at the trough to +160.3%, a 2-quarter improving streak, ROCE slipping at 8.2%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −3.9% | +11.3% | — | — |
| Profit | −24.0% | −7.5% | — | — |
| EPS | −23.8% | −8.5% | — | — |
| Stock price | +107.3% | +31.2% | +38.7% | +17.2% |
4-Factor Sector Score
75.0/100 — rank 1 of 30 in Oil & Gas Midstream · 81% evidence confidence
Frontline plc scores 75.0 out of 100 against the 30 companies it is compared with in Oil & Gas Midstream, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
The four contributions add to the total exactly: 29.1 + 16.9 + 15.4 + 13.6 = 75. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Frontline plc reported $0.7 B of revenue in the Mar 26 quarter, +65.1% year on year. That is the 2nd straight quarter of year-on-year growth. Over 4 years it has compounded at 27.3% a year. The last full year, FY25, came in at $2.0 B. The last four reported quarters add to $2.2 B.
FY25 revenue came in at $2.0 B (−3.9% on the year), capping 4 years at 27.3% compound. The latest quarter (Mar 26) printed $0.7 B, +65.1% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +20.7% growth against the decade's 27.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +17.3% over the last 4 quarters against +8.9%/yr over the last 8 — accelerating; TTM profit +160.0% vs +19.2%/yr — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Frontline plc's operating margin is 83.1% in the Mar 26 quarter, +62.2 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.3% to 41.7%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 83.1%, +62.2 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 1.3%–41.7%.
Why the margin moved: operating margin went +62.2 pp year on year while gross margin went +22.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Frontline plc earned $0.6 B of net profit in the Mar 26 quarter, +1,766.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY25 profit was $0.4 B. That is 78.9% of the quarter's revenue. The same quarter a year earlier earned $0.0 B.
Mar 26 profit was $0.6 B, +1,766.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY25 printed $0.4 B (−24.0%).
Why profit moved: revenue contributed +65.1% and the margin +62.2 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +476.0% vs revenue +20.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 148% of Frontline plc's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.7 B of operating cash against $0.4 B of profit. After $0.0 B of capital spending, $0.7 B was left as free cash.
FY25: operating cash of $0.7 B against reported profit of $0.4 B, leaving free cash of $0.7 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 148% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Frontline plc does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $3.0 B over the last 3 years. Averaged over those years that is 50.8% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $3.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Frontline plc earns a ROE of 15% in FY25. That is up from a trough of −1% in FY21. Return on invested capital clears the cost of that capital by +11.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 19.3% net margin on 0.34× asset turns.
FY25 ROE is 15%, recovered from a FY21 trough of −1% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 19.3% net margin × 0.34× asset turns × 2.29× balance-sheet leverage ≈ 15.0% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 16.8% − 5.3% = a +11.5 pp spread. The 5.3% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Frontline plc paid $3.13 per share over the last four reported quarters, up 761.1% on a year ago. The most recent declaration was $1.55 for Mar 26. Against the current price of $39.0 that is a trailing yield of 8.03%, measured on dividends already paid rather than on a forecast.
Frontline plc paid $3.13 per share across the last four reported quarters, most recently $1.55 for Mar 26. That is up 761.1% against the same quarter a year earlier. Against the current price of $39.0 the trailing twelve months work out to 8.03% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Frontline plc carries total debt of $2.6 B against shareholder equity of $2.8 B as of Mar 26, a debt-to-equity of 0.93. On the annual view that ratio went from 1.45 in FY21 to 1.22 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $2.6 B against shareholder equity of $2.8 B — a debt-to-equity of 0.93. On the annual view, debt-to-equity went from 1.45 (FY21) to 1.22 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
No ownership or positioning reading is held for Frontline plc, so this section names the gap rather than filling it. At typical trading volumes those positions would take about 2.1 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
We hold no ownership or positioning reading for this stock, so this section says that plainly.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Frontline plc: the Z-score reads 2.33. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.33 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.33.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Frontline plcthis pageFRO | 75.0/100Favorable setup81% evidence | ASLEEP | 29.1/35 Revenue 18.5% · PAT 100% · OPM change 60.1 pp 83% evidence | 16.9/25 ROCE 10.8% · OPM 81.9% 76% evidence | 15.4/20 P/E 8.6× · PEG 0.19 65% evidence | 13.6/20 RS sector 12.8% · RS bench 17.7% · 1Y 103.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 29.1 + 16.9 + 15.4 + 13.6 = 75 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2International Seaways, Inc.INSW | 73.9/100Favorable setup81% evidence | FADING | 26.9/35 Revenue 14.5% · PAT 69.3% · OPM change 57.6 pp 83% evidence | 16.5/25 ROCE 11.2% · OPM 89.9% 76% evidence | 16.4/20 P/E 6.6× · PEG 0.09 65% evidence | 14.1/20 RS sector 23.7% · RS bench 29% · 1Y 116%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.9 + 16.5 + 16.4 + 14.1 = 73.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3BW LPG LimitedBWLP | 68.7/100Favorable setup81% evidence | TURNING | 24.3/35 Revenue 5.1% · PAT 31.4% · OPM change 23.6 pp 83% evidence | 15.3/25 ROCE 8% · OPM 26.2% 76% evidence | 15.2/20 P/E 7.3× · PEG 0.28 65% evidence | 13.9/20 RS sector 12.1% · RS bench 17.6% · 1Y 44.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 15.3 + 15.2 + 13.9 = 68.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Cmb.Tech NVCMBT | 64.5/100Mixed-positive evidence71% evidence | FADING | 24.5/35 Revenue 100% · PAT 12.5% · OPM change 40.9 pp 83% evidence | 13.2/25 ROCE 5.8% · OPM 84.6% 76% evidence | 11.2/20 P/E 7.9× · PEG — 15% evidence | 15.6/20 RS sector 13.3% · RS bench 18.8% · 1Y 75.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 24.5 + 13.2 + 11.2 + 15.6 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Targa Resources Corp.TRGP | 60.9/100Mixed-positive evidence81% evidence | BREAKING OUT | 21.2/35 Revenue 1.1% · PAT 44.2% · OPM change 8.8 pp 83% evidence | 12.9/25 ROCE 3.9% · OPM 20.7% 76% evidence | 12.6/20 P/E 25.6× · PEG 0.45 65% evidence | 14.2/20 RS sector 6.2% · RS bench 11.1% · 1Y 59.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 12.9 + 12.6 + 14.2 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Scorpio Tankers Inc.STNG | 58.7/100Thin evidence · provisional58% evidence | ASLEEP | 23.1/35 Revenue — · PAT — · OPM change 42 pp 45% evidence | 15.3/25 ROCE 9.8% · OPM 70.2% 76% evidence | 11.5/20 P/E 4.3× · PEG — 15% evidence | 8.8/20 RS sector -1.4% · RS bench 3.5% · 1Y 67.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 23.1 + 15.3 + 11.5 + 8.8 = 58.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Venture Global, Inc.VG | 55.6/100Mixed-positive evidence81% evidence | TURNING | 17.1/35 Revenue 100% · PAT 81.5% · OPM change -12.3 pp 83% evidence | 9.3/25 ROCE 2.4% · OPM 25% 76% evidence | 14.8/20 P/E 17.5× · PEG 0.14 65% evidence | 14.4/20 RS sector -1.5% · RS bench 3.1% · 1Y 4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 9.3 + 14.8 + 14.4 = 55.6 · Decision use: Price leads the evidence: RS versus the benchmark is 3.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 8Western Midstream Partners, LPWES | 55.3/100Mixed-positive evidence81% evidence | TURNING | 14.5/35 Revenue 11.4% · PAT -6.5% · OPM change -2.9 pp 83% evidence | 14.2/25 ROCE 3.8% · OPM 41.8% 76% evidence | 15.2/20 P/E 13.5× · PEG 0.17 65% evidence | 11.4/20 RS sector -4.1% · RS bench 1.7% · 1Y 22.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.2 + 15.2 + 11.4 = 55.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9Enterprise Products Partners L.P.EPD | 54.1/100Thin evidence · provisional58% evidence | ASLEEP | 22.4/35 Revenue — · PAT — · OPM change 1.8 pp 45% evidence | 14.0/25 ROCE 7.2% · OPM 13.2% 76% evidence | 10.9/20 P/E 12.7× · PEG — 15% evidence | 6.8/20 RS sector -6.8% · RS bench -1.5% · 1Y 21.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 22.4 + 14 + 10.9 + 6.8 = 54.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Plains All American Pipeline, L.P.PAA | 51.9/100Mixed-positive evidence81% evidence | TURNING | 17.1/35 Revenue -7.1% · PAT 45.4% · OPM change 0.1 pp 83% evidence | 6.9/25 ROCE 1.7% · OPM 3.2% 76% evidence | 12.7/20 P/E 18.5× · PEG 0.49 65% evidence | 15.2/20 RS sector 1.1% · RS bench 6.4% · 1Y 31.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6.9 + 12.7 + 15.2 = 51.9 · Decision use: Price leads the evidence: RS versus the benchmark is 6.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 11South Bow CorporationSOBO | 49.2/100Mixed-negative evidence81% evidence | ASLEEP | 13.4/35 Revenue -4.6% · PAT 44.5% · OPM change -3.1 pp 83% evidence | 10.3/25 ROCE 1.7% · OPM 32.6% 76% evidence | 13.5/20 P/E 16.4× · PEG 0.36 65% evidence | 12.0/20 RS sector -0.8% · RS bench 4.5% · 1Y 32%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.4 + 10.3 + 13.5 + 12 = 49.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Golar LNG LimitedGLNG | 48.6/100Mixed-negative evidence81% evidence | ASLEEP | 27.9/35 Revenue 81.5% · PAT 100% · OPM change 76.5 pp 83% evidence | 11.7/25 ROCE 2.7% · OPM 81.8% 76% evidence | 4.3/20 P/E 42.3× · PEG 2.76 65% evidence | 4.7/20 RS sector -6.1% · RS bench -1.3% · 1Y 22.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 27.9 + 11.7 + 4.3 + 4.7 = 48.6 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -6.1% and the one-year return is 22.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 13Pembina Pipeline CorporationPBA | 48.2/100Mixed-negative evidence81% evidence | TURNING | 13.0/35 Revenue -6.5% · PAT -12.8% · OPM change 2.7 pp 83% evidence | 11.3/25 ROCE 2.3% · OPM 37.3% 76% evidence | 13.2/20 P/E 23.4× · PEG 0.33 65% evidence | 10.7/20 RS sector -3.4% · RS bench 2% · 1Y 36.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 11.3 + 13.2 + 10.7 = 48.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 14Hess Midstream LPHESM | 48.1/100Mixed-negative evidence81% evidence | TURNING | 13.0/35 Revenue 7% · PAT 3.6% · OPM change -1.1 pp 83% evidence | 15.4/25 ROCE 5.8% · OPM 61% 76% evidence | 12.2/20 P/E 13.4× · PEG 1.01 65% evidence | 7.5/20 RS sector -8.1% · RS bench -2.7% · 1Y -3.3%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 15.4 + 12.2 + 7.5 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Excelerate Energy, Inc.EE | 46.9/100Mixed-negative evidence81% evidence | BREAKING OUT | 14.2/35 Revenue 39.4% · PAT -6.8% · OPM change -2 pp 83% evidence | 10.4/25 ROCE 2.5% · OPM 18.9% 76% evidence | 4.1/20 P/E 27.2× · PEG 3.91 65% evidence | 18.2/20 RS sector 4.8% · RS bench 10.3% · 1Y 61.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 10.4 + 4.1 + 18.2 = 46.9 · Decision use: Price leads the evidence: RS versus the benchmark is 10.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Kinetik Holdings Inc.KNTK | 46.4/100Mixed-negative evidence81% evidence | ASLEEP | 16.2/35 Revenue 9.3% · PAT 100% · OPM change -5.2 pp 83% evidence | 5.1/25 ROCE -0.1% · OPM -0.9% 76% evidence | 13.9/20 P/E 19.8× · PEG 0.27 65% evidence | 11.2/20 RS sector -3.3% · RS bench 1.9% · 1Y 17.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 5.1 + 13.9 + 11.2 = 46.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Antero Midstream CorporationAM | 46.3/100Thin evidence · provisional58% evidence | ASLEEP | 16.3/35 Revenue — · PAT — · OPM change -0.9 pp 45% evidence | 14.4/25 ROCE 3.1% · OPM 60% 76% evidence | 9.3/20 P/E 27.1× · PEG — 15% evidence | 6.3/20 RS sector -7.5% · RS bench -2.5% · 1Y 18.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.3 + 14.4 + 9.3 + 6.3 = 46.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18The Williams Companies, Inc.WMB | 46.2/100Mixed-negative evidence81% evidence | ASLEEP | 21.6/35 Revenue 10.7% · PAT 22.3% · OPM change 7.7 pp 83% evidence | 12.8/25 ROCE 2.5% · OPM 43.6% 76% evidence | 8.6/20 P/E 31.9× · PEG 1.46 65% evidence | 3.2/20 RS sector -9.2% · RS bench -4.2% · 1Y 23.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 12.8 + 8.6 + 3.2 = 46.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19ONEOK, Inc.OKE | 45.3/100Mixed-negative evidence81% evidence | ASLEEP | 18.6/35 Revenue 41% · PAT 12.1% · OPM change -0.4 pp 83% evidence | 10.7/25 ROCE 2.4% · OPM 14.8% 76% evidence | 8.9/20 P/E 16.1× · PEG 1.68 65% evidence | 7.1/20 RS sector -7.4% · RS bench -2.3% · 1Y 17.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 10.7 + 8.9 + 7.1 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Cheniere Energy Partners, L.P.CQP | 45.1/100Mixed-negative evidence81% evidence | TURNING | 11.2/35 Revenue 21% · PAT 2.5% · OPM change -17.6 pp 83% evidence | 9.0/25 ROCE 2.4% · OPM 10% 76% evidence | 13.5/20 P/E 15.1× · PEG 0.48 65% evidence | 11.4/20 RS sector -3.8% · RS bench 1.6% · 1Y 21.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 9 + 13.5 + 11.4 = 45.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21Kinder Morgan, Inc.KMI | 45.1/100Thin evidence · provisional58% evidence | ASLEEP | 21.2/35 Revenue — · PAT — · OPM change 2.9 pp 45% evidence | 10.8/25 ROCE 2% · OPM 29.9% 76% evidence | 9.7/20 P/E 20.5× · PEG — 15% evidence | 3.4/20 RS sector -11% · RS bench -6% · 1Y 16.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 10.8 + 9.7 + 3.4 = 45.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Energy Transfer LPET | 45.0/100Mixed-negative evidence81% evidence | TURNING | 14.9/35 Revenue 12.5% · PAT -9.5% · OPM change -1.2 pp 83% evidence | 10.8/25 ROCE 2.5% · OPM 10.7% 76% evidence | 9.3/20 P/E 16.1× · PEG 1.67 65% evidence | 10.0/20 RS sector -5.2% · RS bench 0.3% · 1Y 17.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 10.8 + 9.3 + 10 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23MPLX LPMPLX | 43.5/100Mixed-negative evidence81% evidence | TURNING | 11.1/35 Revenue 3.1% · PAT 5.8% · OPM change -4.1 pp 83% evidence | 13.4/25 ROCE 2.8% · OPM 36.1% 76% evidence | 9.0/20 P/E 12.4× · PEG 1.84 65% evidence | 10.0/20 RS sector -6.4% · RS bench -0.7% · 1Y 20%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.1 + 13.4 + 9 + 10 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Plains GP Holdings, L.P.PAGP | 43.1/100Mixed-negative evidence64% evidence | TURNING | 13.2/35 Revenue -7.1% · PAT — · OPM change 0.1 pp 62% evidence | 4.3/25 ROCE 1.6% · OPM 3.2% 76% evidence | 9.5/20 P/E 25× · PEG — 15% evidence | 16.1/20 RS sector 1.9% · RS bench 7.2% · 1Y 32.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 4.3 + 9.5 + 16.1 = 43.1 · Decision use: Price leads the evidence: RS versus the benchmark is 7.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25TC Energy CorporationTRP | 40.1/100Thin evidence · provisional58% evidence | ASLEEP | 18.0/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 8.7/25 ROCE 1.6% · OPM 47.5% 76% evidence | 9.0/20 P/E 28.2× · PEG — 15% evidence | 4.4/20 RS sector -6.8% · RS bench -1.7% · 1Y 32.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 8.7 + 9 + 4.4 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26DT Midstream, Inc.DTM | 39.9/100Thin evidence · provisional58% evidence | ASLEEP | 18.4/35 Revenue — · PAT — · OPM change 0.6 pp 45% evidence | 11.2/25 ROCE 1.8% · OPM 49.4% 76% evidence | 8.7/20 P/E 32.1× · PEG — 15% evidence | 1.6/20 RS sector -9.8% · RS bench -4.8% · 1Y 28.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 11.2 + 8.7 + 1.6 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Viper Energy, Inc.VNOM | 35.5/100Mixed-negative evidence71% evidence | BASING | 12.0/35 Revenue 84.3% · PAT -121.9% · OPM change -13.8 pp 83% evidence | 12.4/25 ROCE 2.8% · OPM 49.5% 76% evidence | 10.4/20 P/E 15.8× · PEG — 15% evidence | 0.7/20 RS sector -13.9% · RS bench -9.1% · 1Y 12%0 of 12 weeks ahead 100% evidence |
| Exact sum: 12 + 12.4 + 10.4 + 0.7 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Enbridge Inc.ENB | 34.6/100Thin evidence · provisional58% evidence | BASING | 15.9/35 Revenue — · PAT — · OPM change -5.4 pp 45% evidence | 7.3/25 ROCE 1.4% · OPM 14.4% 76% evidence | 8.9/20 P/E 29.7× · PEG — 15% evidence | 2.5/20 RS sector -11.6% · RS bench -6.5% · 1Y 13.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 7.3 + 8.9 + 2.5 = 34.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Cheniere Energy, Inc.LNG | 32.4/100Adverse evidence81% evidence | TURNING | 8.3/35 Revenue 20.8% · PAT -37.2% · OPM change -77.1 pp 83% evidence | 3.8/25 ROCE -8.8% · OPM -59.4% 76% evidence | 10.5/20 P/E 46.7× · PEG 0.9 65% evidence | 9.8/20 RS sector -6.4% · RS bench -1.2% · 1Y 11.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.3 + 3.8 + 10.5 + 9.8 = 32.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30SunocoCorp LLCSUNC | 51.4/100Thin evidence · provisional23% evidence | BREAKING OUT | 18.4/35 Revenue — · PAT — · OPM change 2.3 pp 10% evidence | 13.0/25 ROCE 6.8% · OPM 8.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 12 weeks ahead 0% evidence |
| Exact sum: 18.4 + 13 + 10 + 10 = 51.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Frontline plc's stock price today?
Frontline plc trades at $39.0, +107.3% over the past year. The company is valued at $9.0 B. The stock sits at 91% of its 52-week range of $19–$41, +23.7% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 37 weeks in. — as of 5 August 2026.
What were Frontline plc's latest quarterly results?
Frontline plc reported revenue of $0.7 B and net profit of $0.6 B for the Mar 26 quarter. Revenue rose 65.1% and profit rose 1,766.7% year on year. Earnings per share were $2.51. The operating margin was 83.1%, 62.2 pp higher than a year earlier. — as of 5 August 2026.
What is Frontline plc's revenue?
Frontline plc reported revenue of $0.7 B in the Mar 26 quarter, +65.1% year on year. For the full FY25 fiscal year, revenue was $2.0 B (−3.9%). Over the last 4 years revenue compounded at 27.3% a year. — as of 5 August 2026.
What is Frontline plc's profit?
Frontline plc earned $0.6 B of net profit in the Mar 26 quarter, +1,766.7% year on year — the 2nd straight quarter of growth. Full-year FY25 profit was $0.4 B. The operating margin ran 83.1% in the latest quarter. — as of 5 August 2026.
What is Frontline plc's market cap?
Frontline plc's market capitalisation is $9.0 B at a stock price of $39.0. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
What is Frontline plc's P/E ratio?
Frontline plc trades at a P/E of 9.6×, at the 60th percentile of its own 4-year range, against a long-run median of 8.9×. This is a comparison with the stock's own history, not a value call — as of 5 August 2026.
Does Frontline plc pay a dividend?
Yes — Frontline plc declared $1.55 per share for Mar 26, and $3.13 per share across the last four reported quarters. The latest quarter is up 761.1% on the same quarter a year earlier. — as of 5 August 2026.
What is Frontline plc's dividend per share?
Frontline plc's most recently declared dividend is $1.55 per share for Mar 26, giving $3.13 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 5 August 2026.
What is Frontline plc's dividend yield?
Frontline plc's trailing dividend yield is 8.03%: $3.13 declared per share across the last four reported quarters, against a share price of $39.0. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 5 August 2026.
Is Frontline plc overvalued?
On its own history, Frontline plc looks mid-range against its own history: its P/E of 9.6× sits at the 60th percentile of its 4-year range (long-run median 8.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 5 August 2026.
Is Frontline plc growing?
Yes — Frontline plc is growing: latest-quarter revenue +65.1% year on year, profit +1,766.7%, and the margin +62.2 pp at 83.1%. The earnings engine currently reads: improving — as of 5 August 2026.
How is Frontline plc performing?
Frontline plc is in a confirmed uptrend, 37 weeks in. Its latest quarter's revenue rose 65.1% and profit rose 1,766.7% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
What stage is Frontline plc in?
Turning around — EPS growth swung from −59.8% at the trough to +160.3%, a 2-quarter improving streak, ROCE slipping at 8.2%. The read comes from the last 12 quarters of growth (revenue growth +17.3% latest, profit growth +160.0% latest, eps growth +160.3% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 5 August 2026.
Is Frontline plc in an uptrend?
Yes — the price is in a confirmed uptrend (week 37 of stage 2), trading +23.7% versus its 200-day average and at 91% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Frontline plc beating the market?
Not lately — on a trailing-13-week view Frontline plc is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.1 years the stock moved +418% against the S&P 500's +263% — ahead of the index over the full window. — as of 5 August 2026.
Will Frontline plc's stock price go up?
This page publishes no price forecast for Frontline plc. What it measures instead: the stock price is $39.0, the price is in a confirmed uptrend 37 weeks in. Its P/E of 9.6× sits at the 60th percentile of its own 4-year range. — as of 5 August 2026.
Does Frontline plc have too much debt?
It is moderate — Frontline plc's debt-to-equity is 0.93. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 5 August 2026.
What is Frontline plc's capex?
Frontline plc spent $3.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Frontline plc's cash flow?
Frontline plc generated $0.7 B of operating cash flow in FY25 and $0.7 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.4 B, so operating cash ran ahead of profit. — as of 5 August 2026.
Is Frontline plc's profit real cash?
Yes — over the last 3 fiscal years, 148% of Frontline plc's reported profit arrived as operating cash. In FY25, operating cash was $0.7 B against reported profit of $0.4 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 5 August 2026.
How financially safe is Frontline plc?
On the balance sheet, the Z-score reads 2.33 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 5 August 2026.
Where is Frontline plc in its business cycle?
Frontline plc's FY25 operating margin was 30.5%, against a 5-year band of 1.3%–41.7%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 83.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Frontline plc story?
The sharpest disagreement: the price moved +107.3% in a year while annual EPS moved −23.8% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Frontline plc a stock worth studying right now?
This is not investment advice. The machine read: Frontline plc's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.